Tetra Bio-Pharma Inc. (TSXV:TBP) ('Tetra') entered into a share purchase agreement to acquire remaining 20% stake in PhytoPain Pharma Inc. (‘PhytoPain’) from André Rancourt, Chairman of the Board of Tetra, and Guy Chamberland, Chief Scientific Officer of Tetra (collectively ‘sellers’), for CAD 13 million on January 2, 2018. Under the terms, Tetra will pay CAD 248,000 in cash, promissory note of CAD 2,236,696 payable on achievement of certain milestones, issue 2,485,218 shares to sellers on closing of transaction and issue an additional 7,444,653 shares to an escrow agent. Upon completion of the transaction, PhytoPain Pharma will become a wholly-owned subsidiary of Tetra. Tetra intends to use a portion of the proceeds from a CAD 10 million offering of units to partially repay the Promissory Notes which will be issued in connection with the acquisition of PhytoPain. The transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange and any other approval that may be required by the TSX. The transaction has been unanimously approved by Tetra’s Board of Directors. The transaction will be completed in the first quarter of 2018.